Complex Made Simple

Hikma forecasts 20% increase in 2013 revenue on strong doxycycline sales

London-headquartered Hikma Pharmaceuticals has raised its full-year revenue forecast for the third time in four months this year, on the back of strong sales of its generic antibiotic doxycycline, Reuters has reported. The company said it expected total revenue to rise 20% in 2013, up from its previous forecast of 17%. Strong doxycycline sales had prompted Hikma to raise its full-year revenue growth forecast to 17% last month, up from 13%.